OptimizeRx (OPRX)

Nasdaq Market Closed

OptimizeRx Corporation is a digital health technology company serving the U.S. healthcare and life sciences markets. Its platform is designed to help pharmaceutical, biotech, and other healthcare organizations communicate with healthcare professionals and patients at key points in the care journey. The company operates at the intersection of healthcare marketing, clinical workflow technology, and patient engagement.

OptimizeRx’s network is embedded across a range of digital channels used by physicians and other healthcare professionals, including electronic health record and e-prescribing environments. Through these integrations, the company enables life sciences brands to deliver educational messages, therapy information, affordability support, and other resources in contexts where treatment decisions are being considered. Its tools also support direct-to-consumer outreach, allowing clients to coordinate engagement across both professional and patient audiences.

The company’s value proposition is based on relevance, timing, and measurable engagement. Rather than relying solely on traditional advertising, OptimizeRx uses data and technology to target communications to appropriate audiences while supporting compliance with healthcare industry standards. Its services can be used for product launches, adherence programs, patient acquisition campaigns, and ongoing brand support.

OptimizeRx competes in a market shaped by the digitization of healthcare, the growing importance of electronic clinical workflows, and life sciences companies’ need for more efficient commercial strategies. Its platform connects healthcare professionals, patients, and pharmaceutical brands through an omnichannel model, making it a specialized participant in the broader healthcare technology and digital marketing ecosystem.

5.38 USD
5.15 USD
+0.43 (+8.69%)
After-hours

Last updated

Market Cap
92.89M
P/E
13.59
P/FCF
6.48
P/S
0.87
Enterprise Value
96.06M
Sector
Industrials
Industry
Business Services, Not Elsewhere Classified
Address
260 CHARLES STREET, WALTHAM, MA, 02453
GlobeNewswire Inc.

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network

17 Dec 2025, 15:00 PM
GlobeNewswire Inc.

OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

11 Mar 2025, 17:00 PM
GlobeNewswire Inc.

New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations

20 Jun 2024, 17:00 PM
GlobeNewswire Inc.

OptimizeRx Reports First Quarter 2024 Financial Results

15 May 2024, 01:31 AM
Zacks Investment Research

Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?

13 May 2024, 19:25 PM
GlobeNewswire Inc.

OptimizeRx to Participate in Upcoming Investor Conferences

07 May 2024, 02:00 AM
GlobeNewswire Inc.

OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET

26 Apr 2024, 17:00 PM
Zacks Investment Research

After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)

23 Apr 2024, 19:05 PM
Zacks Investment Research

Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)

22 Apr 2024, 19:05 PM
GlobeNewswire Inc.

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report

18 Apr 2024, 17:00 PM
GlobeNewswire Inc.

OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row

11 Apr 2024, 17:00 PM
GlobeNewswire Inc.

OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET

25 Mar 2024, 17:00 PM
GlobeNewswire Inc.

OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023

12 Mar 2024, 02:00 AM
GlobeNewswire Inc.

OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community’ Outreach Effort

05 Mar 2024, 02:21 AM
GlobeNewswire Inc.

OptimizeRx to Participate in Upcoming Investor Conferences

21 Feb 2024, 18:00 PM
Zacks Investment Research

Bruker (BRKR) Q4 Earnings and Revenues Top Estimates

13 Feb 2024, 19:15 PM
GlobeNewswire Inc.

OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

25 Jan 2024, 18:00 PM
GlobeNewswire Inc.

OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update

09 Jan 2024, 18:00 PM
GlobeNewswire Inc.

OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco

18 Dec 2023, 18:00 PM
Zacks Investment Research

OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?

11 Dec 2023, 22:30 PM
Market Cap
92.89M
Enterprise Value
96.06M
P/E
13.59
P/B
0.72
P/S
0.87
EV / EBITDA
5.09
EV / Sales
0.89
EPS
0.36
Dividend Yield
0%
P/FCF
6.48
P/CF
6.46
Free Cash Flow
14.33M
ROE
5.27%
ROA
4.09%
Debt / Equity
0.18
Current Ratio
5.37
Quick Ratio
5.37
Cash
1.93
Avg Volume
488.08K
Fundamentals Snapshot Price
4.95

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 19.84M 32.24M 26.07M 29.2M 21.93M
Gross profit 14.93M 24.1M 17.52M 18.64M 13.34M
Operating income 396K 8.57M 2.05M 3.19M -2.1M
EBITDA 1.46M 10.02M 3.13M 4.26M -1.01M
Net income -495K 5.02M 779K 1.53M -2.2M
Basic EPS -0.03 0.27 0.04 0.08 -0.12
Diluted EPS -0.03 0.26 0.04 0.08 -0.12

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 167.26M 176.92M 170.32M 169.27M 167.77M
Total liabilities 37.65M 48.62M 48.06M 49.98M 51.5M
Total equity 129.61M 128.29M 122.26M 119.28M 116.27M
Cash & equivalents 20.17M 23.37M 19.52M 16.59M 16.57M
Current assets 56.17M 64.72M 56.32M 54.08M 51.71M
Current liabilities 10.46M 21.26M 18.47M 21.06M 18.35M

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow -467K 7.09M 3.2M 4.56M 3.86M
Investing cash flow -21K 206K -10K -44K -84K
Financing cash flow -2.71M -3.45M -258K -4.51M -587K
Change in cash -3.2M 3.85M 2.93M 12K 3.19M
Kind Filing Date Link
edgar index DEFA14A — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
form 4 Form 4 — Silvestro Stephen L View Filing
form 4 Form 4 — Greco Theresa View Filing
form 4 Form 4 — Greco Theresa View Filing
edgar index 10-Q — OptimizeRx Corp View Filing
edgar index 8-K — OptimizeRx Corp View Filing
eight k text 8-K — 8-K View Filing
edgar index 3 — OptimizeRx Corp View Filing
edgar index 8-K — OptimizeRx Corp View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — OptimizeRx Corp View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — OptimizeRx Corp View Filing
edgar index 10-K — OptimizeRx Corp View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
edgar index 8-K — OptimizeRx Corp View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — OptimizeRx Corp View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
edgar index 4/A — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4/A — OptimizeRx Corp View Filing
form 4 Form 4 — Stelmakh Edward View Filing
form 4 Form 4 — Besch Doug View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
form 4 Form 4 — Silvestro Stephen L View Filing
form 4 Form 4 — Greco Theresa View Filing
form 4 Form 4 — Silvestro Stephen L View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
form 4 Form 4 — Besch Doug View Filing
form 4 Form 4 — Besch Doug View Filing
form 4 Form 4 — Besch Doug View Filing
form 4 Form 4 — D'Silva Andrew J. View Filing
form 4 Form 4 — Merrell Brendan W. View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
form 4 Form 4 — Odence-Ford Marion View Filing
form 4 Form 4 — Silvestro Stephen L View Filing
form 4 Form 4 — Silvestro Stephen L View Filing
form 4 Form 4 — Silvestro Stephen L View Filing
form 4 Form 4 — Stelmakh Edward View Filing
form 4 Form 4 — Stelmakh Edward View Filing
form 4 Form 4 — Stelmakh Edward View Filing
form 4 Form 4 — Stelmakh Edward View Filing
form 4 Form 4 — Stelmakh Edward View Filing
form 4 Form 4 — Stelmakh Edward View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
form 4 Form 4 — D'Silva Andrew J. View Filing
form 4 Form 4 — Merrell Brendan W. View Filing
edgar index 3 — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
form 3 Form 3 — Merrell Brendan W. View Filing
form 3 Form 3 — Merrell Brendan W. View Filing
form 3 Form 3 — Merrell Brendan W. View Filing
form 3 Form 3 — Merrell Brendan W. View Filing
form 3 Form 3 — Merrell Brendan W. View Filing
edgar index 10-Q — OptimizeRx Corp View Filing
edgar index 4 — OptimizeRx Corp View Filing
edgar index 8-K — OptimizeRx Corp View Filing